- Home
- MKTW vs ARTV Comparison
MKTW vs ARTV Comparison
Compare MKTW & ARTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MKTW
- ARTV
- Stock Information
- Founded
- MKTW 1999
- ARTV 2019
- Country
- MKTW United States
- ARTV United States
- Employees
- MKTW N/A
- ARTV N/A
- Industry
- MKTW Computer Software: Prepackaged Software
- ARTV
- Sector
- MKTW Technology
- ARTV
- Exchange
- MKTW Nasdaq
- ARTV NYSE
- Market Cap
- MKTW 48.2M
- ARTV 39.0M
- IPO Year
- MKTW N/A
- ARTV 2024
- Fundamental
- Price
- MKTW $20.12
- ARTV $1.61
- Analyst Decision
- MKTW
- ARTV Strong Buy
- Analyst Count
- MKTW 0
- ARTV 8
- Target Price
- MKTW N/A
- ARTV $18.14
- AVG Volume (30 Days)
- MKTW 18.2K
- ARTV 303.9K
- Earning Date
- MKTW 08-13-2025
- ARTV 08-28-2025
- Dividend Yield
- MKTW 4.00%
- ARTV N/A
- EPS Growth
- MKTW 207.28
- ARTV N/A
- EPS
- MKTW 3.12
- ARTV N/A
- Revenue
- MKTW $383,217,000.00
- ARTV N/A
- Revenue This Year
- MKTW N/A
- ARTV N/A
- Revenue Next Year
- MKTW N/A
- ARTV N/A
- P/E Ratio
- MKTW $6.40
- ARTV N/A
- Revenue Growth
- MKTW N/A
- ARTV N/A
- 52 Week Low
- MKTW $9.08
- ARTV $1.47
- 52 Week High
- MKTW $24.20
- ARTV $17.31
- Technical
- Relative Strength Index (RSI)
- MKTW 64.85
- ARTV N/A
- Support Level
- MKTW $19.21
- ARTV N/A
- Resistance Level
- MKTW $20.12
- ARTV N/A
- Average True Range (ATR)
- MKTW 0.80
- ARTV 0.00
- MACD
- MKTW 0.07
- ARTV 0.00
- Stochastic Oscillator
- MKTW 91.61
- ARTV 0.00
About MKTW MarketWise Inc.
Marketwise Inc is a multi-brand subscription services platform providing premium financial research, software, education, and tools for investors. Its products are built for high-value financial research, education, actionable investment ideas, and investment software. It is a digital, direct-to-consumer company offering its research across a variety of platforms including mobile, desktops, and tablets.
About ARTV ARTIVA BIOTHERAPEUTICS INC
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).